KleinC, ChiuY, AwniW, ZhuT, HeuserR, DoanT. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr, 2007; 44:401–410.
2.
MurphyR, BrunS, HicksCet al.ABT-378/ritonavir plusstavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48 week results. AIDS, 2001; 15:1–9.
3.
MeynardJ, Morand-JoubertL, LacombeKet al.Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: The Kaledose trial. J Antimicrob Chemother, 2010; 65:125–128.
4.
Van der LugtJ, AutarRS, UbolyamSet al.Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1–infected adults. J Antimicrob Chemother, 2008; 61:1145–1153.
5.
HillA, Van der LugtJ, BoffitoM. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS, 2009; 23:2237–2245.
6.
JacksonA, HillA, PulsRet al.Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. J Antimicrob Chemother, 2011; 66:635–640.
